RPG Life Sciences Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-f80534f28fb15c188eaadd3d.pdf

Key Takeaways


Domestic Formulations: The Inventory & Supply Reset

Ashok Nair: "We had almost had a 4-day inventory reduction there. Second, one of our key third-party manufacturers, we almost had supply challenges... However, I'm happy to say that all those things have been cleared in October. In fact, we almost recovered some of the sales which we lost in September due to the supply challenges which we faced. So if you look without that impact, our DF would have been actually at 15.2% growth..."

API: The Quarter Everything Changed

Ashok Nair: "If you see our CAGR growth over next 3 to 5 years including both organic and inorganic should be at least 30% for us, which means our API business should at least be at INR300 to INR350 crore by FY30 and INR500 crore by FY32, subject to further acquisitions as well."

International Formulations: The Turnaround Bet

Ashok Nair: "First is this will be our first product which will be OTC in the global space. Second, it is the only second product in Canada where the originator is there and we are. So we believe that at least to start off, 25% to 30% of market share to come to us."

Margins & Costs: Investing Through the Cycle

Amol Lone: "Our primary focus is also on the growth. Uh, I mean, when we are doing a lot of activities, uh, towards the growth of the business, I think, uh, we probably will have to compromise little bit on the bottom line because when we are getting into the new segment of the competitors, and there are expenses and there are things which you'll have to do."

Market Position & Competitive Momentum

Ashok Nair: "Our approach remains one of discipline, cautious optimism, delivering today's commitment while investing in tomorrow's growth."

Guidance & Commitments

CommitmentSpecificsTimeline
Acquired API revenue contribution₹25–30 crore revenue in H2; EBITDA margin in mid-20sH2 FY27
API business CAGRAt least 30% (organic + inorganic)3–5 years
API revenue target₹300–350 croreBy FY30
API revenue target₹500 crore, subject to further acquisitionsBy FY32
Domestic formulations growthGrow at 1.5x market growthComing quarters
International formulations growthDouble-digit growthFrom H2 FY27
Naprosyn Canada market share25–30% initial shareStarting mid-December 2026
International formulations revenueAdd ~₹10 crore from Chile and EthiopiaFrom FY29
International formulations revenueAdd ~₹8 crore from UK renewal projectFrom FY29
International formulations R&D pipelineTarget ~₹25 croreBy FY30
EBITDA marginAspire to reach back to ~25%Ongoing
CapExRemain below 7–8% of salesOngoing
Employee costsNormalized at current levelGoing forward

Key Metrics

MetricQ2 FY27
Revenue from operations₹211.6 cr, +16.5% YoY; almost entirely organic, acquired sites contributed only ₹50 lakhs
Adjusted EBITDA₹50.1 cr, +15% YoY; excludes ₹5.5 cr one-time restructuring and acquisition-linked costs
Adjusted EBITDA margin23.7% (₹50.1 cr on ₹211.6 cr revenue), vs 24.0% in Q2 FY26 (per an analyst's math)
Gross marginExpanded 260 bps YoY, despite West Asia war impact on input costs
PBT before exceptional items₹42.5 cr, +11.3% YoY
H1 FY27 revenue₹407.3 cr, +16.2% YoY
H1 FY27 adjusted EBITDA₹97.9 cr, margin at 24.0%, +16.1% YoY
Domestic formulations revenue₹145.7 cr, +11.6% YoY; 70% of total revenue; growth would have been 15.2% excluding supply challenges and inventory reduction
Domestic formulations volume growth (H1)6.8%, almost twice the market growth of 3.4%
API business revenue₹27.5 cr, +85.5% YoY; entirely organic
International formulations revenue₹36.7 cr, +6.4% YoY
Naprosyn H1 primary sales₹47.9 cr, +13.6% YoY; crossed ₹100 cr in secondary sales on a MAT basis
FY26 launched brands H1 FY27 sales₹12.4 cr, nearly double the ₹6.3 cr in H1 FY26
PCPM (per capita per month)₹7.7 lakhs, up from ₹6.5 lakhs last year
One-time restructuring and acquisition-linked costs₹5.5 cr, impacting reported PBT
Acquired API entities H2 FY27 revenue guidance₹25–30 cr (directionally), billing commenced Q3
API business CAGR target (organic + inorganic, 3–5 years)At least 30%, targeting ₹300–350 cr by FY30 and ₹500 cr by FY32